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Abstract (275 words)  
Background and aims:  Patients with refractory ascites (RA) require repeated large volume 
paracenteses (LVP), which involves frequent hospital visits and is associated with poor 
quality-of-life. This study assessed safety and efficacy of an automated, low-flow pump 
(alfapump [AP]) compared with LVP [SoC].  
 
Methods: Randomized, controlled trial, in 7 centers, with 6M patient observation. Primary 
outcome was time to first LVP. Secondary outcomes included paracentesis requirement, 
safety, health-related quality-of-life (HRQoL), and survival. Nutrition and hemodynamics 
were assessed in a sub-study at 3M.  
 
Results: 60 patients randomized and 58 were analyzed (27-AP, 31-SoC, mean age 61.9y, 
mean MELD 11.7). Eighteen patients were included in the sub-study. Compared with SoC, 
median time to first LVP was not reached after 6 months in the AP group, meaning a 
significant reduction in LVP requirement for the AP patients (AP, median not reached ; SoC, 
15.0 days (95%CI 13.0, 22.0); HR: 0.13, p<0.001), and Chronic Liver Disease Questionnaire 
(HRQoL) score (p<0.05 between treatment arms). Improvements in nutritional parameters 
were observed for hand-grip strength (p=0.044) and body mass index (p<0.001) in the sub-
study. Compared with SoC, more AP patients reported adverse events (AEs; 96.3% vs. 
77.4%, p=0.057) and serious AEs (85.2 vs. 45.2%, p=0.002). AEs consisted predominantly of 
acute kidney injury in the immediate post-operative period, and re-intervention for pump 
related issues, and were treatable in most cases. Survival was similar in AP and SoC.  
Conclusions: The AP system is effective in reducing need for paracentesis and improving 
HRQoL in cirrhotic patients with RA.  Although the frequency of SAEs (and by inference 
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hospitalizations) were significantly higher in the AP group, they were generally limited and 
did not impact survival. www.clinicaltrials.gov#NCT01528410 
 
Keywords: refractory ascites; liver cirrhosis; paracentesis  
 
Lay Summary: The alfapump moves abdominal fluid into the bladder from where it is then 
removed by urination. Compared with standard treatment, the alfapump reduces the need 
for large volume paracentesis (manual fluid removal by needle) in patients with medically 
untreatable ascites. This can improve life quality for these patients.  
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Introduction  
Accumulation of ascites is a common complication of cirrhosis and one of the leading 
reasons for hospital admission [1] . Approximately 60% of cirrhotic patients develop ascites 
within 10 years of diagnosis. Treatment of ascites includes restriction of dietary sodium and 
diuretics [2]. However, some patients develop diuretic-resistant or intractable ascites, 
because of diuretic-induced complications such as renal dysfunction, hyponatremia or 
hepatic encephalopathy (HE) [3, 4]. 
 
Current guidelines for the treatment of refractory ascites (RA) are large volume paracentesis 
(LVP) [5] with albumin infusion to decrease the risk of paracentesis-induced circulatory 
dysfunction (PICD) [6]. Although LVP is considered safe, it requires patient hospital contact 
as often as weekly and is associated with poor quality of life and malnutrition, which 
together increase morbidity and mortality [7, 8].  
 
In selected patients with RA, a transjugular intrahepatic portosystemic shunt (TIPS) is a 
therapeutic alternative to repeated LVPs [9]. Unfortunately, TIPS is contraindicated in 
patients with marked pulmonary arterial hypertension, heart failure, advanced liver disease, 
significant hepatic encephalopathy, uncontrollable coagulopathy, and elevated right or left 
heart pressures [10]. Orthotopic liver transplantation is the only definitive treatment for RA, 
but availability is limited by organ availability, relatively low MELD scores that disadvantage 
RA patients on transplant waiting lists, and attendant costs [11]. Therefore, repeated LVP is 
the mainstay of treatment of RA. 
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The poor nutrition and decreased quality of life in RA patients treated with repeated LVPs, 
the Automated Low-Flow Ascites Pump System (alfapump
®
 system, Sequana Medical AG, 
Zurich, Switzerland (Supplementary Figure 1), was developed as an alternative to LVP. The 
alfapump is a fully implantable, programmable, and rechargeable pump system that 
automatically diverts ascitic fluid from the peritoneal cavity to the urinary bladder, allowing 
fluid removal by micturition. The system allows remote monitoring of fluid transport and 
tailored therapy dependant upon ascites production. The alfapump system is intended to 
provide an alternative treatment for RA, which may improve HRQoL and nutrition by 
reducing repeated LVPs in those patients who are not candidates for TIPS. PIONEER, a 
prospective, open label, uncontrolled study, demonstrated the safety of the alfapump 
system and a significant reduction in the need for paracentesis in patients with RA. The 
study, however, lacked a control group [12].  
 
The aim of this study was to perform a randomized and controlled study to evaluate the 
safety and efficacy of the alfapump system in cirrhotic patients with RA in comparison with 
LVP.  
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Materials and methods  
Ethics 
The study was approved by the ethics committees at all centers and registered on 
www.clinicaltrials.gov, #NCT01528410). Each patient gave written, informed consent in 
accordance with the principles of the Declaration of Helsinki of the World Medical 
Association [13]. All authors had access to the study data and reviewed and approved the 
final manuscript. 
 
Definitions  
Refractory ascites: Ascites that cannot be mobilized or early recurrence of which (i.e., after 
therapeutic paracentesis) that cannot be satisfactorily prevented by medical therapy [3].  
Acute Kidney Injury (AKI): All episodes of AKI (increase in serum creatinine of 0.3 mg/dL 
within 48 hours, or >50% from baseline within the prior 7 d [14, 15], and renal insufficiency 
will be referred to as AKI. 
Large Volume Paracentesis [16] : Removal of ≥5 L of ascitic fluid from the peritoneal cavity.  
Paracentesis: Any therapeutic paracentesis including LVP but not including diagnostic 
paracentesis. 
 
Study design and procedures 
This prospective, multicenter, open-label, randomized, controlled study of patients with RA 
due to cirrhosis was performed at seven centers from five countries: United Kingdom, 
France, Austria, Spain and Italy (Supplemental Table 1). Randomised patients were followed 
for a nominal 180-day treatment phase, after which SoC patients were able to switch to the 
alfapump system study arm. An exploratory sub-study was performed on the first 18 
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patients enrolled at the Royal Free Hospital in London, to investigate the effects of the 
alfapump system on nutrition, hemodynamics and biomarkers of renal injury, after 90 d.  
 
Paracentesis was carried out, when required, using study site standard protocols. Patients 
randomized to the AP arm received antibiotic prophylaxis (norfloxacin 400 mg/day or 
ciprofloxacin 750 mg/week) for study duration. Diuretic therapy was discontinued after 
implantation in all patients randomized to the AP arm, and re-started at investigator 
discretion if required. SoC group patients maintained their pre-study diuretic therapy 
regimen; changes to diuretic dosages were allowed at investigator discretion but were 
reduced or stopped in case of diuretic-related complications. Abstinence from alcohol and 
controlled salt intake were recommended for both groups throughout the study duration.  
 
The alfapump was surgically inserted subcutaneously in the upper right quadrant of the 
abdomen, as described [12]. Perioperative antibiotics (ceftazidime 2 g and teicoplanin 
400 mg pre-surgery and again 12 h post surgery) were recommended; deviations were 
allowed according to local practice. The alfapump system was activated the day after 
surgery. If necessary, pump parameters such as the targeted daily pump volume and the 
time of day during which the pump is active were adjusted during patient visits. Fluid 
transport by the alfapump was monitored remotely. Initial pump settings were estimated 
from the patient’s paracentesis history and subsequently modified based on patient weight 
and volume of ascitic fluid present.  
 
The schedule of visits was identical for both groups after the initial 7 d and included visits at 
Day 7, 14, 21, 30, 60, 90, and 180. AP patients were assessed daily during the period of 
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hospitalization following alfapump implantation, whereas SoC patients were only seen 
during the first 7 days if necessary.  For relevant comparison, safety is reported including 
and excluding the 7-day post-implant period. Albumin administration was at the discretion 
of the investigator and specifically indicated for (a) paracentesis, (b) spontaneous bacterial 
peritonitis and (c) episodes of acute kidney injury, and also for episodes of hyponatremia. 
Patients enrolled in the sub-study underwent additional assessments at baseline, Day 30, 
and Day 90.  
 
Eligibility 
Males and non-pregnant females ≥18 years old with liver cirrhosis (based upon histological 
features, ultrasound, or clinical signs including ascites, hepatic encephalopathy, 
thrombocytopenia, and splenomegaly) and RA requiring periodic LVP (≥5 L) and albumin 
administration [4] were included (Supplementary Table 2). Subjects also needed to 
demonstrate willingness to comply with study procedures, the ability to operate the device, 
and centers were advised not to enroll subjects eligible for TIPS. Further exclusion criteria 
are listed in Supplimentary table 2.  
 
 
Primary endpoint was time to first LVP. Paracentesis was indicated when the patient 
complained of tense ascites and timing at investigator discresion. Secondary endpoints 
included overall paracentesis requirement, overall safety including renal injury and 
infections, a disease-specific health-related quality of life (HRQoL) instrument (chronic liver 
disease questionnaire (CLDQ)), and survival. Surgical, anesthetic and device-related 
complications in the treatment group were measured. Economic outcomes included 
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number and cost of study visits, paracentesis visits, AE related visits and hospitalizations, 
over 6 months. In the sub-study, nutritional status including BMI, hand grip, mid-arm muscle 
circumference (MAMC), triceps skin fold thickness (TSF), and the Royal Free Hospital 
General Assessment (RFH-GA) [17] were measured. Additionally, hemodynamic markers and 
biomarkers of renal injury including cardiac index, systemic vascular resistance, plasma 
renin activity, kidney injury molecule-1 (KIM-1) and urinary neutrophil gelatinase-associated 
lipocalin (NGAL) were measured for sub-study patients. 
 
Statistics and sample size 
Patients were randomized to either the alfapump system group (treatment group AP) or LVP 
group (treatment group SoC) by a centralized, computer-generated method to achieve a 1:1 
ratio. Over 6 months, 71% of AP patients are expected to require LVP [12]. Conservatively 
estimating 97% of SoC patients require LVP over 6 months equates to a hazard ratio 
(SoC:AP) of 2.83 [18]. Based on the assumption of proportional hazards, a log-rank test of 
equality of survival distributions, with a 5% two-sided significance level and 90% power 
requires 23 LVP events per group, requiring a sample size equivalent to 28 patients per 
group and 56 in total. 
Analyses were carried out using SPSS Version 23.0, SAS Version 9.3 or higher, and R version 
3.2.2. Descriptive analysis was performed for all primary and secondary variables. 
Continuous variables were described with means, medians, standard deviation, 95% 
confidence interval, minimum and maximum values of each distribution, and interquartile 
range (IQR). Categorical variables were described using frequencies and percentage of 
patients in each category.  
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Time to LVP and survival time were compared using Kaplan-Meier estimators and log-rank 
tests. Other parameters were compared using appropriate methods depending on the type.  
 
HRQoL data were systematically collected for study participants at baseline, 1-, 2-, 3- and 6-
months’ time points. The QoL scores were compared between the treatment arms using a 
non-parametric rank sum test, and to patients' own baseline levels using a sign rank test.  
 
Economic analysis 
A within-trial economic analysis was performed using a bottom-up approach [19], and from 
the perspective of the National Health-Care System (NHS) in the UK.  Only direct costs were 
included as follows: costs for alfapump implantation , costs of LVP, costs of typical 
management of ascites (laboratory tests, medications, scheduled visits), and costs related to 
AE treatment. For analysis of resource use and AEs costs: the AE category was determined 
using data on hospitalization requirement, elective vs. non-elective admission, diagnosis, 
and provided treatment; events were grouped for a single patient if they were reported 
during the same admission or out-patient visits, payment mechanism and costs were 
estimated for groups of events or individual events. 
 
For cost estimates of treatment in each treatment arm, quantities of resource use were 
multiplied by their corresponding unit costs. Pharmaceuticals costs were estimated using 
British National Formulary [20], Drugs and Pharmaceutical Electronic Market Information 
Tool [21] and National Health Services Drug Tariff for England and Wales [22].Cost of 
physician/nurse visits was estimated using data from Personal Social Services Research Unit 
[23] and cost of hospital and out-patient specialist care was based on UK Departments’ of 
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Health NHS Reference cost [24]. All costs were presented using 2015/2016 British Pounds. 
Inflation adjustments were made using Hospital & Community Health Services index. 
For descriptive analyses for resource use and costs, median and interquartile range were 
used, Mann-Whitney U test was used for comparison between groups. 
 
Sub-Study 
The sub-study was designed to provide descriptive data and assess the effect of the 
alfapump on the measured parameters. A power calculation was not possible, as no prior 
data existed. A sample size of 18 patients (1:1 ratio AP versus SoC) was sufficient for the 
exploratory objectives of the sub-study. 
The data were interpreted using an analysis of covariance using the baseline measure as the 
covariate. Plasma renin values were log10 transformed for analysis. Nutritional data were 
on an ordinal scale, whereby the three categories were ordered. These data were analyzed 
by the Cochran-Mantel-Haenszel procedure. The one and three-month data were stratified 
by their baseline category. The three ordered categories were assumed to be equally 
spaced. 
 
Results  
Baseline Characteristics and Patient Disposition 
Between July 2012 and February 2015, 216 potential patients were pre-screened, and 81 
patients signed informed consent. Most commonly unmet inclusion/exclusion criteria were; 
significantly decreased life expectancy or high anesthetic risk (comorbidity) (8.3%), unwilling 
to give consent (7.4%) no refractory ascites requiring LVP (6.5%), renal failure (6.5%), death 
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before enrolment (5.6%), or advanced hepatocarcinoma (5.1%). Of the 81 consented 
patients, 60 patients met ultimate eligibility criteria and were randomized (screening and 
exclusion summary given in Supplemental Table 2) and constitute the intent-to-treat (ITT) 
population. Following randomization, 29 were allocated to the alfapump system treatment 
arm (AP) and 31 to the LVP standard of care (SoC) control arm. Ultimately, 58 patients – 27 
patients in the AP group and 31 patients in the SoC group – received the designated 
treatment and constitute the safety population. Of these 58 patients, 17/27 (63%) in the AP 
group and 21/31 (68%) in the SoC group completed the study, and 10 from each study arm 
withdrew due to serious adverse events (SAEs), death, or other reasons. Median time on 
study was equivalent in both groups and details are provided in the CONSORT diagram 
(Figure 1). 
 
Baseline characteristics and patient demographics were well-balanced, with no significant 
differences between the two treatment groups (Table 1). The mean age of patients in the 
AP group was 61.1±8.5 years vs. 62.6±8.4 years in the SoC group. In both groups, 
approximately 80% of patients were male, mean MELD scores were 12.2±2.5 and 11.3±3.9, 
and mean Child-Pugh scores of 8.2±1.1 and 8.4±1.1 for the AP and SoC groups, respectively. 
Most patients in both groups were Child-Pugh Class B and alcohol was the most common 
etiology of cirrhosis. Median time since the requirement for paracentesis was 1.1 (IQR 1, 2) 
and 1.0 years (IQR 1, 2) in the AP and SoC groups, respectively. Previous hospitalization 
(within 3 months of study entry) for a cirrhosis complication occurred in 52% of AP and 68% 
of SoC group patients and contraindications to TIPS included coronary artery disease/heart 
failure, hepatic encephalopathy, non-functioning TIPS, portal vein thrombosis, pulmonary 
hypertension, anticoagulation, and patient discretion.  
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Sub-study: The first 18 eligible patients at RFH were randomized to the sub-study and of 
these, 16 patients were included in the final analysis, eight in each group. One patient 
developed urinary retention before pump insertion and was withdrawn in the AP group, and 
one withdrew consent in the SoC group. Patient characteristics and demographic baseline 
data including the median age of patients, etiology of cirrhosis and the MELD scores were 
similar as shown in Table 1.  
 
Implant Procedure and Antibiotic Prophylaxis 
In the AP group, 96.3% (26/27) patients received primary or secondary antibiotic 
prophylaxis for spontaneous bacterial peritonitis versus 80.6% (25/31) in the SoC group.  
Mean duration of implant procedure was 65.0 ± 20.6 min (min. 30, max. 130), all were 
performed under general anesthesia (12 laparoscopically [44.4%], 15 open [55.6%]). 
 
Efficacy 
Time to first LVP was significantly greater in the AP group compared with SoC (HR: 0.13, 
p<0.001; Figure 2). The median number of LVP was significantly higher in the SoC group 
compared with the AP group wherein median time to first LVP was not reached after 6 
months (risk ratio SoC/AP [CI]: 7.7 [3.6 to 16.7] p<0.001) as was the median number of 
events/patient as shown in Figure 2. Of the total number of LVP events, 90% occurred in the 
SoC group.  
 
LVP was required in 90% (28 patients) of the SoC group and 37% (10 patients) of the AP 
group. Of those in the AP group that required LVP, 4 patients accounted for 68% of all 
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paracenteses, the causes of which are listed in Supplemental Table 3. One AP group patient 
had the pump removed on Day 8 due to infection and required 7 post-explant LVPs. 
 
Health-related quality of life (Chronic Liver Disease Questionnaire) 
The disease-specific instrument, Chronic Liver Disease Questionnaire (CLDQ) was used to 
measure health-related quality of life (HRQoL) [25]. The Abdominal Symptoms and Activity 
scores improved significantly only in RA patients treated with alfapump (p<0.05 both when 
compared to baseline and between treatment arms). The average improvements in score 
after 3 months of treatment with alfapump were +1.25 and +0.80, respectively, on a 1-7 
scale; notably, these improvements were sustained in AP group patients for months and 
substantially exceed the thresholds of clinical importance [26]. At the same time, no 
significant improvement in any HRQoL scores was observed in SoC group patients (Figure 3). 
Changes in QoL were not significantly different at 6 months. 
 
Nutrition  
Using the RFA-GA tool in the sub-study, improvement in nutritional status from baseline to 
Day 90 was seen in 4/8 (50%) patients in the AP group and none of the SoC group. In the 4 
patients who improved in the AP group, 3/4 improved within 30 days and 1 improved after 
90 days. In the AP group, 5/8 (63%) patients were “adequately nourished” at 90 days versus 
only 3/9 (33%) in the SoC group, and only 1 (13%) patient in the AP group did not complete 
90 days versus 3 (33%) in the SoC group. Overall, there was a trend to improved nutritional 
status in the AP group compared with SoC (p=0.099 at Day 30 and p=0.090 at Day 90. 
Nutritional parameters are shown in Table 2. Compared with the SoC group, there were 
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statistically significant improvements seen in body mass index (BMI), mid-arm muscle 
circumference, tricipital skin fold thickness, and hand grip strength in the AP group.  
 
Health economic analysis 
Median number of out-patient visits (3 [IQR 2, 9] vs 2 [IQR 1, 3.8] in SoC group, p<0.001) and 
hospitalizations (2 [IQR 2, 4] vs 1 [IQR 0.25, 1.5], p<0.001) due to adverse events (AEs) was 
higher in AP group compared with SoC group at 6 months.  A total and breakdown of costs is 
provided in Supplementary Table 10. Total median cost of (0-180 days), including 
implantation procedure and device, scheduled visits, lab test, medications and treatment of 
adverse events was significantly higher in AP group (£36970 [IQR 29910, 46850]) relative to 
SoC group (£12660 [IQR 7972, 18100], p<0.0001). The difference is primarily due to the 
statistically higher cost of implantation procedure (including cost of the device) (£22230 [IQR 
21560, 23630] vs. £0 respectively, p<0.001) and AE events (£3983 [IQR 1789, 9432] vs. 
£1504 [IQR 2, 5126] for AP vs. SoC respectively, p=0.002) . The cost of paracentesis was 
statistically higher in SoC group compared with AP group (£7254 [IQR 3711, 13550] vs £1682 
[IQR 0-3796], p<0.001). For post 3 month (1-90 days), AP group had significantly higher cost 
for scheduled visits, AE events and lab test relative to SoC group, but significantly lower cost 
for paracentesis relative to SoC group (p<0.0001). For post 3-6 month (91-180 days), the AP 
group had significantly lower cost for paracentesis relative to SoC group (p<0.0001). No 
significant differences were found for any other cost items between the two groups. There 
was no significant trend towards higher cost for the period of 1-90 days post-implantation 
(excluding cost of implantation procedure and device) in AP group vs SoC group (£1496 [IQR 
1360-1496] vs £952 [816-1088] respectively, p=0.181) and lower total cost for the period of 
91-180 days (£1704 [IQR 308-3574] vs £3265 [328-6613] respectively, p=0.348). 
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Safety  
More patients in the AP group had at least one treatment-emergent adverse event (TEAE) 
than in the SoC group (96.3% versus 77.4%, p=0.057) and there were approximately twice as 
many in the AP group (199) compared with the SoC group (97) or 7.4 and 3.1 per patient, 
respectively. Compared with SoC, approximately twice as many AP patients had serious 
TEAEs (85.2% versus 45.2%, p=0.002) and there were 64 serious TEAEs in the AP group and 
27 in the SoC group, or 2.4 and 0.9 per patient, respectively, as noted in Table 3. 
 
Of serious TEAEs, there were statistically more AP group patients with nervous system 
disorders (2 with hepatic encephalopathy, the others related to electrolyte abnormalities, 
alcohol withdrawal, and stroke; p=0.042), and renal and urinary disorders (p<0.001).  
Procedural complications were observed in the AP patients and these are summarised in 
Table 3. 
 
Survival  
There was no significant difference in overall survival (including off-treatment) between the 
AP and SoC groups (p=0.355) as shown in Supplementary Figure 2. Six patients in the 
alfapump group and 4 patients in the SoC arm died during the 6-month study period. One 
death in the AP group occurred shortly after withdrawl from the study (still within 6 
months) following recovery from pump explant for infection. Causes of death are consistent 
with advanced liver disease and are shown in Supplemental Table 4. 
 
Infection 
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TEAEs due to infection are shown in detail in Supplemental Table 5. Twenty-five patients in 
the AP group suffered treatment emergent infections with 23 fully recovering, 1 recovered 
with sequelae, and 1 deceased (sepsis), compared with 30 infections in the SoC group 
wherein 26 fully recovered, 3 were ongoing or outcome was unknown, and 1 deceased 
(SBP). Specifically, the incidences of spontaneous bacterial peritonitis and urinary tract 
infections were similar. The nature and frequency of patients with SAEs due to infection 
were similar in each group (p=0.883) as can be seen in Supplementary Table 5 and Table 3 
(SAE by outcome section) .  
 
Circulatory dysfunction 
Acute kidney injury  
More than 50% of the AP group patients experienced SAEs related to the renal and urinary 
system. Except for 3 patients with hematuria and urethral stenosis, the others were due to 
AKI. Just over 41% of these AEs in the AP group (12/29) occurred in the first 7 days after 
implant and were transient, and of those 10/12 fully recovered and 2/12 improved 
(Supplemental Table 6). There were significantly more AKI events in the AP group than in 
the SoC group (29 vs. 11, respectively; p=0.007). If the first 7 post-operative days are 
excluded, there were similar numbers in each group (17 vs. 11, respectively; p=0.281, Table 
3). One patient in the AP group with alcoholic liver disease and a history of hepatic 
encephalopathy died of end-stage liver disease and liver failure 52 days after implantation. 
This was caused by septic shock and consequent AKI that occurred on the background of a 
severely infected diabetic foot requiring amputation. 
 
Serum creatinine 
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There was no significant change from baseline in creatinine levels between or within groups 
at any time point. The means, medians and interquartile ranges (IQR) of changes in serum 
creatinine are shown in Supplementary Table 9. 
 
Serum albumin 
The fall in albumin (g/L) over time was significantly greater in the AP group than SoC at Days 
60, 90, and 180 (Supplementary Table 9). The AP group received significantly less total 
albumin after Day 0 over the course of the study than the SoC group (Supplementary Figure 
5) and in the AP group, albumin was administered predominantly for renal insufficiency. In 
addition to infusion during LVP, albumin was administered in the SoC group for similar 
reasons.  
 
Hyponatremia 
There were 7 hyponatremia-related AEs in 5 patients in the AP group, 3 of which required 
hospital admission and all occurred > 7 days after the implant.  There were  3 hyponatremia 
AEs in 3 patients in the SoC group, one of which required hospitalisation and all occurred > 7 
days after randomization. Each of these episodes was readily corrected with fluid restriction 
and/or volume resuscitation. 
 
Hemodynamics, plasma renin activity, and inflammatory biomarkers including markers of 
kidney injury  
In the sub-study, no significant changes were noted in cardiac index, mean arterial pressure, 
heart rate, stroke volume, or plasma B-type natriuretic peptide.  A trend was noted 
suggesting an increase in both systemic vascular resistance (SVR, p=0.129) and plasma renin 
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activity (p=0.144) at 3 months but not at 1 month.  A statistically significant rise in NGAL was 
noted at 3 months (p=0.043) but no significant differences were noted for kidney injury 
molecule-1 (KIM-1), tumor necrosis factor, IL6, IL1β, white cell count, or C-reactive protein. 
These are shown in Supplemental Tables 7 and 8. 
 
Reinterventions 
Of the 27 AP group patients, 12 patients were reported with at least one device deficiency, 
7 patients required reintervention due to device deficiency,  6 (22%) required system 
component replacement or repositioning and 3 (11%) required system explant as detailed in 
Table 4. All fully recovered. No patients discontinued the study due to device deficiency. Of 
the 17 patients who completed the study, 11 did so without pump system reintervention 
although 2 required replacement chargers, and 7 of 10 patients who withdrew or died did 
so inspite of fully functioning pump system (although 1 required charger replacement and 2 
required pump system explant due to pump pocket infection). Overall 66.6% of implanted 
systems functioned without reintervention until study completion, withdrawal or death. 
 
Discussion 
This study is the first randomized, controlled clinical trial that investigates the safety and 
efficacy of the alfapump system to treat RA compared with a control cohort managed with 
LVP. The data add to the existing body of evidence confirming that the alfapump system is 
efficacious in reducing, and in many cases eliminating, the need for paracentesis. This 
reduction was associated with significant improvements in HRQoL and nutrition. Although 
the total number of infectious complications was similar between groups, there were 
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significantly more AKI events in the AP patients, the overall outcomes from which were not 
different between the groups.  
 
The alfapump system is designed to obviate the need for paracentesis and successfully 
eliminated the need for LVP in more than 50% of implanted patients over 6 months. The 
majority of necessary LVPs were attributable to catheter blockage or migration and this 
remains an area of potential improvement in device design. Renal dysfunction, resulting in 
the decision to reduce the programmed rate of daily fluid transport in 2 patients, was also a 
contributing factor and may also be an area where device programming and peri-implant 
care protocols including albumin administration may be desirable.  
 
Although there was no significant difference between groups in the number of AEs related 
to AKI and hyponatremia occurring >7 days after implantation, more of these events 
required hospitalization in the AP group. The underlying mechanism for this renal 
dysfunction and hyponatremia remains unclear and may be related to gradual albumin 
depletion, resulting in circulatory dysfunction as evidenced by an increase in plasma renin 
activity. Recently reported haemodynamic observations, correlated to alfapump treatment, 
are hypothesised to indicate treatment-related change in effective arterial blood volume, 
which mimics postparacentesis circulatory dysfunction syndrome [27]. The events occurring 
within the first seven days following implant may also be related to sterile inflammation 
induced by the surgical procedure or related to manipulation of the abdominal wall and 
rapidly changing abdominal pressures, or both. It is also possible that prophylactic 
perisurgical administration of albumin may help prevent these transient episodes of AKI and 
electrolyte imbalance, a point also noted by Sola et al.[27] However, it is important to note 
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that despite the lack of albumin substitution and significant reduction in albumin levels in 
the AP group, there was no significant difference in change from baseline in creatinine, 
number of patients with infection, or overall survival between groups.  
 
The QoL data collected during this study show a marked improvement in QoL scores, 
especially in the first 3 months of treatment. This is important because patients with 
advanced liver disease and RA suffer from very marked impairment of QoL. This increase in 
QoL reflects significant improvement of patients’ experience with their liver disease. 
Nevertheless, it is important to note that patients with refractory ascites generally have high 
6-month mortality. Furthermore, a number of these patients are expected to receive liver 
transplants. In this context, the number of patients who remained in the study and 
completed QoL questionnaires at the later study time points was limited, dampening the 
power of the study and statistical significance of QoL score improvements. 
 
Implantation of the alfapump system was associated with improvements in nutritional 
status compared with the SoC group measured by improved BMI, hand grip, TSF and MMAC, 
compared with the LVP group. Due to the small number of patients evaluable at 6-months 
and the design of the sub-study, it remains unclear if these nutritional benefits extend for 
periods longer than 3-months. Additionally, the mechanism by which this nutritional benefit 
occurs is unknown but may involve attenuation of the increased resting energy expenditure 
associated with ascites [28].The improvements noted were similar to the improvements in 
body composition and resting energy expenditure seen following TIPS insertion [29, 30]. 
 
  
 25
Three pumps were explanted due to pump pocket issues such as infection or wound 
dehiscence. Clearly, wound infection or dehiscence limits the utility of the alfapump system 
and is problematic in patients with decompensated cirrhosis who are generally 
compromised with poor wound healing. Device deficiencies accounted for 7 re-
interventions and no patients discontinued for this reason. This is an improvement 
compared to the results of the PIONEER study and may reflect the continual technological 
improvements to the alfapump system since commercialization in 2011.  
 
Despite higher implantation cost for alfapump (£22,230), for the post-intervention cost, in 
AP group there was a trend towards stabilized costs, while in SoC group there was a steady 
increase mainly caused by high costs of paracentesis. Further improvements for the 
Alfapump in surgical protocols, post-implant care procedures, and system configuration e.g. 
catheter design, antibiotic coatings, and pump shape may help to reduce the cost for AP, 
and improve the cost-effectiveness of the alfapump. Further investigations with longer 
follow-up time are needed, to better understand the economic value of AP. 
 
In conclusion, results of this study show that the alfapump system was effective in 
significantly reducing the need for paracentesis and improving HRQoL in those with 
refractory ascites due to cirrhosis and improved overall nutrition in a non-selected subset of 
those patients. Although SAEs were more common in the AP group these were generally 
limited and did not affect overall survival at 6 months. The impact of refinements in patient 
selection, patient care algorithms - including regular albumin administration to reduce the 
risk of circulatory dysfunction and infection - as well as modifications in device design 
remain areas for future study.  
  
 26
 
Acknowledgements  
Editorial support was provided by Dr Diana Shy from Medicalwriters.com (Zurich, 
Switzerland). 
  
  
 27
References: 
 
1. Planas, R., et al., Natural history of patients hospitalized for management of cirrhotic 
ascites. Clin Gastroenterol Hepatol, 2006. 4(11): p. 1385-94. 
2. Runyon, B.A. and A.P.G. Committee, Management of adult patients with ascites due 
to cirrhosis: an update. Hepatology, 2009. 49(6): p. 2087-107. 
3. Arroyo, V. and P. Gines, Arteriolar vasodilation and the pathogenesis of the 
hyperdynamic circulation and renal sodium and water retention in cirrhosis. 
Gastroenterology, 1992. 102(3): p. 1077. 
4. Moore, K.P. and G.P. Aithal, Guidelines on the management of ascites in cirrhosis. 
Gut, 2006. 55 Suppl 6: p. vi1-12. 
5. European Association for the Study of the, L., EASL clinical practice guidelines on 
the management of ascites, spontaneous bacterial peritonitis, and hepatorenal 
syndrome in cirrhosis. J Hepatol, 2010. 53(3): p. 397-417. 
6. Gines, P., et al., Randomized comparative study of therapeutic paracentesis with and 
without intravenous albumin in cirrhosis. Gastroenterology, 1988. 94(6): p. 1493-502. 
7. Barsuk, J.H., et al., Clinical outcomes after bedside and interventional radiology 
paracentesis procedures. Am J Med, 2013. 126(4): p. 349-56. 
8. Barsuk, J.H., et al., Specialties performing paracentesis procedures at university 
hospitals: implications for training and certification. J Hosp Med, 2014. 9(3): p. 162-8. 
9. Gines, P., et al., Transjugular intrahepatic portosystemic shunting versus 
paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology, 2002. 
123(6): p. 1839-47. 
10. American College of Radiology, Society for Pediatric Radiology, and Society for 
Interventional Radiology, ACR-SIR-SPR practice parameter for the creation of a 
transjugular intrahepatic portosystemic shunt (TIPS), Amended 2014 (Resolution 39). 
Practice Parameters and Technical Standards, 2014: p. 1-22. 
11. Heuman, D.M., et al., Persistent ascites and low serum sodium identify patients with 
cirrhosis and low MELD scores who are at high risk for early death. Hepatology, 
2004. 40(4): p. 802-10. 
12. Bellot, P., et al., Automated low flow pump system for the treatment of refractory 
ascites: a multi-center safety and efficacy study. J Hepatol, 2013. 58(5): p. 922-7. 
13. Williams, J.R., The Declaration of Helsinki and public health. Bull World Health 
Organ, 2008. 86(8): p. 650-2. 
  
 28
14. Angeli, P., et al., Diagnosis and management of acute kidney injury in patients with 
cirrhosis: revised consensus recommendations of the International Club of Ascites. J 
Hepatol, 2015. 62(4): p. 968-74. 
15. Mehta, R.L., et al., Acute Kidney Injury Network: report of an initiative to improve 
outcomes in acute kidney injury. Crit Care, 2007. 11(2): p. R31. 
16. Bernardi, M., et al., Albumin infusion in patients undergoing large-volume 
paracentesis: a meta-analysis of randomized trials. Hepatology, 2012. 55(4): p. 
1172-81. 
17. Morgan, M.Y., et al., Derivation and validation of a new global method for assessing 
nutritional status in patients with cirrhosis. Hepatology, 2006. 44(4): p. 823-35. 
18. Campbell, M.J., D. Machin, and S.J. Walters, Medical Statistics: A Textbook for the 
Health Sciences. 2010, Wiley. 
19. Glick, H.A., et al., Economic Evaluation in Clinical Trials. 2014: Oxford University 
Press. 
20. Joint Formulary Committee, British National Formulary (BNF) 70. 2015, London: BMJ 
Publishing Group Ltd and Royal Pharmaceutical Society. 
21. Department of Health UK. Drugs and pharmaceutical electronic market information 
(eMit). 2016  [cited 2016 February 30]; Available from: 
https://www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-
market-information-emit  
22. NHS Business Services Authority and NHS Prescription Services, National Health 
Service Drug Tariff for England and Wales, D.o. Health, Editor. 2016, Department of 
Health: London. 
23. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2014. 
2014 2014 [cited 2016 February 2]; Available from: http://www.pssru.ac.uk/project-
pages/unit-costs/2014/  
24. Department of Health. National Schedule of Reference Costs Year : 2014 – 2015. 
2016 2016 [cited 2017 February 2]; Available from: 
https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015  
25. Younossi, Z.M., et al., Development of a disease specific questionnaire to measure 
health related quality of life in patients with chronic liver disease. Gut, 1999. 45(2): p. 
295-300. 
26. Canadian Agency for Drugs and Technologies in Health. APPENDIX 5 VALIDITY OF 
OUTCOME MEASURES;  Sofosbuvir (Sovaldi): Sofosbuvir is Indicated for the 
Treatment of Chronic Hepatitis C Virus (CHC) Infection in Adult Patients With 
  
 29
Compensated Liver Disease, Including Cirrhosis 2014  [cited 2016 2 Dec]; Available 
from: http://www.ncbi.nlm.nih.gov/books/NBK253697/. 
27. Sola, E., et al., Effects of alfapump system on kidney and circulatory function in 
patients with cirrhosis and refractory ascites. Liver Transpl, 2017. 23(5): p. 583-593. 
28. Dolz, C., et al., Ascites increases the resting energy expenditure in liver cirrhosis. 
Gastroenterology, 1991. 100(3): p. 738-44. 
29. Dasarathy, J., N. Alkhouri, and S. Dasarathy, Changes in body composition after 
transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature. 
Liver Int, 2011. 31(9): p. 1250-8. 
30. Plauth, M., et al., Weight gain after transjugular intrahepatic portosystemic shunt is 
associated with improvement in body composition in malnourished patients with 
cirrhosis and hypermetabolism. J Hepatol, 2004. 40(2): p. 228-33. 
 
 
 
 
 
 
 
 
 
 
  
  
 30
Figure legends: 
Figure 1. CONSORT flow diagram of patient enrollment, allocation, follow-up, and analysis. 
 
Figure 2. A, Kaplan-Meier plot comparing the time until the first large volume paracentesis 
(LVP) between alfapump group patients and standard of care LVP–treated patients. P values 
from log-rank test; Hazard ratio from Cox proportional hazards regression model. B and C, 
Box and whisker plots of mean and median paracentesis and LVP per patient, and per 
patient per 28 day month, for the AP (blue) and SoC (red) patient groups. The solid circles 
inside the box and numbers inside or above the box are the means, the horizontal bar inside 
the box (red) and forming the bottom of the box (blue) are the medians, as denoted by the 
number beside the box. Upper and lower quartiles are indicated by the upper and lower 
extent of the box and the extremes represented by the whiskers. Significant differences 
between AP and SoC for all measures noted, p<0.001 determined by two-sided t-test.  D, 
Cumulative incidence of LVP and paracentesis events, with number at risk through time. Per 
protocol, patients were considered to complete the study after their 6-month visit at Day 
180 ± 20. One patient in the SoC group completed the study on Day 234 with last recorded 
paracentesis on Day 119. Paracentesis is defined as any needle stick paracentesis for the 
purpose of ascites removal (not sampling) after Day 0 until withdrawal or completion. LVP 
defined as any paracentesis (as above) of 5 L or more. Significant differences between AP 
and SoC for both AP and SoC noted, p<0.001 (two-sided t-test) 
Figure 3. Prospectively collected HRQoL Chronic Liver Disease Questionnaire (CLDQ) 
abdominal and activity scores by the treatment arm. Both scores significantly higher in the 
AP group as compared to the SoC group when compared to baseline and between 
treatment arms (p<0.05; two-sided t-test). 
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Table Headings: 
Table 1. Baseline demographic and clinical characteristics 
Table 2. Nutritional parameters 
Table 3. Treatment emergent adverse events and treatment emergent serious adverse 
events.  
Table 4. Reinterventions 
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Table 1. Baseline characteristics 
 AP 
N=27 
SoC 
N=31 P-value† 
Substudy 
N=16 
Not in 
Substudy 
N=42 
P-value† 
Age (years), mean (SD) 61.1 (8.5) 62.6 (8.4) 0.537 62.3 (7.5) 61.8 (8.8) 0.787 
Gender (male), n (%) 21 (77.8%) 25 (80.6%) 1 12 (75.0%) 34 (81.0%) 0.720 
BMI (kg/m²), mean (SD) 27.7 (4.8) 27.3 (5.7) 0.596 26.8 (4.5) 27.8 (5.6) 0.676 
MELD Score, mean (SD) 12.2 (2.5) 11.3 (3.9) 0.121 12.8 (3.9) 11.5 (2.9) 0.438 
Child-Pugh score, mean (SD)  8.2 (1.1) 8.4 (1.1) 0.78 8.1 (1.3) 8.4 (1.0) 0.341 
Child Pugh Class, n (%) 
  
0.855 
  
0.975 B 22 (81.5%) 24 (77.4%) 13/15 (86.7%) 
33/39 
(84.6%) 
C 3 (11.1%) 5 (16.1%) 2/15 (13.3%) 6/39 (15.4%) 
Etiology of Liver Cirrhosis, n (%) 
   
   
Alcohol 20 (74.1%) 21 (67.7%) 
0.773 
9 (56.3%) 32 (76.2%) 
0.197 
Non-alcohol 7 (25.9%) 10 (32.3%) 7 (43.8%) 10 (23.8%) 
Time since start of paracentesis 
treatment (years), mean (SD)  1.1 (1, 2) 1.0 (1, 2) 0.397 1.1 (0.8) 1.6 (1.7) 0.670 
Platelets, 109/L mean (SD) 135 (78) 138 (53) 0.887 116 (47) 148 (73) 0.142 
Albumin, g/L mean (SD) 33.7 (6.1) 31.0 (5.2) 0.075 35.1 (6.0) 31.4 (5.6) 0.022 
History prior to enrolment       
Renal failure, n 11 (40.7%) 6 (19,4%) 0.163 9 (56.3%) 9 (21.4%) 0.024 
Hepatorenal syndrome, n 3 (11.1%0 4 (12.9%) 1.000 3 (18.8%) 5 (12.2%) 0.673 
Hepatic encephalopathy, n 8 (29.6%) 9 (29.0%) 0.784 6 (37.5%) 12 (29.3%) 0.545 
Spontaneous bacterial 
peritonitis, n 7 (25.9%) 7 (22.6%) 0.764 4 (25.0%) 10 (24.4%) 1.000 
Urinary infection, n 1 (3.7%) 3 (9.7%) 0.617 0 (0%) 4 (9.8%) 0.568 
Variceal haemorrhage, n 11 (40.7%) 6 (19.4%) 0.090 6 (37.5%) 11 (26.2%) 0.520 
Hospitalized in previous 3 months, n 
(%)* 14 (52%) 21 (68%) 0.285 15 (93.8%) 20 (47.6%) 0.002 
Contraindications to TIPS, n (%) AP N=27 
SoC 
N=31     
Coronary artery disease / heart 
failure 4 (14.8%) 6 (19.4%) - - - - 
Hepatic encephalopathy 9 (33.3%) 9 (29.0%) - - - - 
Non-functioning TIPS 1 (3.7%) 2 (6.5%) - - - - 
Portal vein thrombosis 2 (7.4%) - - - - - 
Pulmonary hypertension - 1 (3.2%) - - - - 
Anticoagulated 1 (3.7%) - - - - - 
Child-Pugh Class C 3 (11.1%) 5 (16.1%) - - -  
Unknown** 9 (33.3%) 11 (35.5%) - - - - 
Time on study (days), mean (SD) 174 (59) 184 (47) 0.431 174 (66) 181 (47) 0.379 
 *all overnight hospitalizations in both groups due to liver disease including those for paracenteses, spontaneous bacterial peritonitis, and 
TIPS and transplant evaluations 
**investigator or patient choice 
AP, alfapump system; SoC, Standard of Care; SD, standard deviation; TIPS, transjugular intrahepatic portosystemic shunt. †All p-values 
Chi-Square test except Mann-Whitney U (Age, BMI, MELD, Child-Pugh score, time since start of paracentesis, and time on study) 
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Table 2. Nutritional parameters 
 Baseline Day 30 Day 90 
Parameter AP SoC AP SoC AP SoC 
Royal Free Hospital General Assessment, n (%)       
Adequately Nourished 2 (25.0) 4 (50.0) 4 (50.0) 4 (50.0) 4 (66.7) 3 (50.0) 
Moderately Malnourished 5 (62.5) 2 (25.0) 4 (50.0) 2 (25.0) 2 (33.3) 1 (16.7) 
Severely Malnourished 1 (12.5) 2 (25.0) 0 (0) 2 (25.0) 0 (0) 2 (33.3) 
 P-Value* - 0.099 0.090 
BMI (kg/m2) N   7 8 6 7 
 Adjusted change1 - - 1.237 -0.145 1.992 -0.650 
P-Value - 0.056 <0.001 
TSF (mm) N   7 8 6 6 
 Adjusted change1 - - 0.466 -0.432 1.898 -0.848 
P-Value - 0.137 0.003 
MAMC (cm) N   7 8 6 6 
 Adjusted change1 - - 0.89 -0.24 1.80 0.16 
P-Value - 0.010 0.008 
Hand-grip (kg) N   7 8 6 6 
 Adjusted change1 - - 2.44 0.84 4.03 -1.69 
P-Value - 0.447 0.044 
*Nourishment data were on an ordinal scale, whereby the three categories were ordered. These data were analyzed by the Cochran-
Mantel-Haenszel procedure, in which the one- and three-month data were stratified by their baseline category. For the analysis, the three 
ordered categories were assumed to be equally spaced.  
1 Mean change from baseline adjusted for the baseline mean by an analysis of covariance  
AP, alfapump system; SoC, Standard of Care; BMI, body mass index, TSF, tricipital skin fold thickness; 
MAMC, mid arm muscle circumference 
 
 
  
  
 38
Table 3. Treatment emergent adverse events and treatment emergent serious adverse 
events 
Treatment emergent adverse events 
(TEAE) 
All ≤ 7 days > 7 days 
AP 
N=27 
SoC 
N=31 P-value AP SoC P-value AP SoC P-value 
Patients with at least one TEAE, n 
(%) 26 (96.3) 24 (77.4) 0.057 22 (81.5) 9 (29.0) <0.001 26 (96.3) 24 (77.4) 0.057 
Total number of TEAEs, n 199 97  50 10  149 87  
Average number of TEAEs/patient, n 7.4 3.1  1.9 0.3  5.5 2.8  
Patients with at least one serious 
TEAE, n (%) 23 (85.2) 14 (45.2) 0.002 9 (33.3) 1 (3.2) 0.004 23 (85.2) 13 (41.9) 0.001 
Number of serious TEAEs, n 64 27  NA NA  NA NA  
Average number of serious 
TEAEs/patient, n 2.4 0.9  NA NA  NA NA  
Summary of Patients w.  Treatment 
Emergent SAEs, n (%) 
AP 
N=27 
SoC 
N=31 P-value AP SoC P-value AP SoC P-value 
Blood and lymphatic system 
disorders, n (%) 1 (3.7) 0 0.466 0 0 1.0 1 (3.7) 0 0.466 
Cardiac disorders, n (%) 0 1 (3.2) 1.0 0 0 1.0 0 1 (3.2) 1.0 
Gastrointestinal disorders, n (%) 7 (25.9) 2 (6.5) 0.068 1 (3.7) 0 0.466 6 (22.2) 2 (6.5) 0.129 
General disorders and administration 
site conditions, n (%) 4 (14.8) 1 (3.2) 0.173 0 0 1.0 4 (14.8) 1 (3.2) 0.173 
Hepatobiliary disorders, n (%) 4 (14.8) 3 (9.7) 0.694 0 0 1.0 4 (14.8) 3 (9.7) 0.694 
Infections and infestations, n (%) 9 (33.3) 8 (25.8) 0.574 2 (7.4) 1 (3.2) 0.593 0 0 1.0 
Injury, poisoning and procedural 
complications, n (%) 3 (11.1) 0 0.095 3 (11.1) 0 0.095 0 0 1.0 
Investigations, n (%) 0 1 (3.2) 1.0 0 0 1.0 0 1 (3.2) 1.0 
Metabolism and nutrition disorders, n 
(%) 4 (14.8) 1 (3.2) 0.173 0 0 1.0 4 (14.8) 1 (3.2) 0.173 
Nervous system disorders, n (%) 6 (22.2) 1 (3.2) 0.042 0 0 1.0 6 (22.2) 1 (3.2) 0.042 
Psychiatric disorders, n (%) 1 (3.7) 0 0.466 1 (3.7) 0 0.466 0 0 1.0 
Renal and urinary disorders, n (%) 14 (51.9) 3 (9.7) <0.001 4 (14.8) 0 0.041 10 (37.0) 3 (9.7) 0.025 
Respiratory, thoracic and mediastinal 
disorders, n (%) 1 (3.7) 0 0.466 0 0 1.0 1 (3.7) 0 0.466 
Counting is on a per-patient basis AP, alfapump system; SoC, Standard of Care; SAE, serious Adverse Event 
Summary of Treatment Emergent 
Serious Adverse Events, by 
Outcome and System Organ Class n 
Outcome 
Alfapump group (n=27) Total FR RS OI OU OW DI 
Injury, poisoning and procedural 
complications 3 3 - - - - - 
General disorders and administration 
site conditions 4 3 - 1 - - - 
Renal and urinary disorders 19 12 1 3 1 1 1 
Gastrointestinal disorders 8 7 - 1 - - - 
Infections and infestations 13 12 - - - - 1 
Metabolism and nutrition disorders 4 3 - 1 - - - 
Hepatobiliary disorders 4 - 1 1 - - 2 
Respiratory, thoracic and mediastinal 
disorders 1 - - - - - 1 
Psychiatric disorders 1 1 - - - - - 
Nervous system disorders 6 5 - - 1 - - 
Blood and lymphatic system disorders 1 - - - 1 - - 
Standard of Care Group (n=31)         
General disorders and administration 
site conditions 1 1 - - - - - 
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Renal and urinary disorders 3 2 - 1 - - - 
Gastrointestinal disorders 2 1 1 - - - - 
Infections and infestations 13 12 - - - - 1 
Metabolism and nutrition disorders 2 - 2 - - - - 
Hepatobiliary disorders 3 - - - 1 - 2 
Nervous system disorders 1 - - 1 - - - 
Cardiac Disorders 1 - - - - - 1 
Investigations 1 1 - - - - - 
Counting is per event. FR = Fully recovered, RS = Recovered with sequelae, OI = Ongoing - Improved, OU = Ongoing - Unchanged, OW = 
Ongoing - Worsened, DI = Died.   
Summaries of Acute Kidney injury 
and Infectious events 
AKI† 
All 
AKI† 
>7 days after implant Infection 
AP 
N=27 
SoC 
N=31 
AP SoC AP SoC 
Total Events 30 11 17 11 25 30 
Events per patient, mean 1.07 0.35 0.63 0.35 1.07 0.35 
Events per patient, range 0 – 3 0 – 5 0 – 3 0 – 5 0 – 3 0 – 4 
P value 0.007 0.281 0.883 
* analyzed by t-test for equality of means  
†acute kidney injury or renal insufficiency or hepatorenal syndrome 
AP, alfapump system; SoC, Standard of Care 
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 AKI† 
All 
AKI†  
>7 days after implant 
Infection 
 AP 
N=27 
SoC 
N=31 
AP SoC AP SoC 
Total Events 30 11 17 11 25 30 
Events/Patient       
Mean 1.07 0.35 0.63 0.35 0.93 0.97 
Range 0 – 3 0 – 5 0 – 3 0 – 5 0 – 3 0 – 4 
P-Value* 0.007 0.281 0.883 
* analyzed by t-test for equality of means  
†acute kidney injury or renal insufficiency or hepatorenal syndrome 
AP, alfapump system; SoC, Standard of Care 
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Table 4. Reinterventions 
Issue 
Time to 
re-intervention 
(days)* 
Intervention Anesthesia / Type Outcome 
alfapump 
    
Lack of communication pump and 
charger 
 
94 
Pump exchange General / Open FR 
Bladder catheter (BC)     
Kinked 
 
5 
BC repositioned and 
pump exchange† 
General / Laparoscopy FR 
Dislocated 20 BC exchange Local / Laparoscopy FR 
Dislocated 113 BC exchange Local / Interventional 
radiology 
FR 
Peritoneal catheter (PC)     
Disconnected 
 
6 
PC and BC repositioned 
and pump exchange† 
Local / Open FR 
Dislocated and occluded 177 PC and pump exchange
†
 General / Open FR 
alfapump system (AP)     
SBP / cellulitis / UTI 8 System explant Unknown FR 
Pocket hematoma / abscess 50 System explant General / Laparoscopy FR 
UTI /pocket abscess / wound 
dehiscence /  
79 System explant General / Laparoscopy FR 
FR, fully recovered; UTI, urinary tract infection; SBP, spontaneous bacterial peritonitis; BC, bladder catheter; PC, peritoneal catheter 
*prophylactic pump exchanges performed at time of catheter re-interventions due to failure of a patency test or a potential issue with 
pump function 
†after implantation 
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Highlights 
 
• alfapump reduces LVP requirement in patients with refractory 
ascities 
 
• alfapump improves 6-month HRQoL compared to SoC in patients 
with refractory ascities 
 
• sub-study alfapump patients showed nutrition cf. SoC in patients 
with ascities 
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